Feb 6 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2018 REVENUE.SEES FY 2018 REVENUE $33.1 MILLION TO $33.4 MILLION.SEES Q4 2018 REVENUE $7.3 MILLION TO $7.6 MILLION.Q4 REVENUE VIEW $7.1 MILLION -- REFINITIV IBES DATA.FY2018 REVENUE VIEW $32.7 MILLION -- REFINITIV IBES DATA.EXPECTS TO ACHIEVE FULL YEAR REVENUE OF $100 MILLION IN 2023 AND TO ACHIEVE A GROSS MARGIN OF 50% BY YEAR END 2023.
Full Article
Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 LOSS PER SHARE $0.16.Q3 REVENUE ROSE 24 PERCENT TO $9.4 MILLION.
Full Article
Nov 1 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.CHEMBIO DIAGNOSTICS - PRICING OF UNDERWRITTEN REGISTERED PUBLIC OFFERING OF 2.4 MILLION SHARES OF ITS COMMON STOCK AT OFFERING PRICE OF $6.75 PER SHARE.
Full Article
Sept 18 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS INC - MAY OFFER FROM TIME TO TIME COMMON STOCK, PREFERRED STOCK, WARRANTS AND UNITS - SEC FILING.CHEMBIO DIAGNOSTICS-MAY ALSO ISSUE ANY OF COMMON STOCK, PREFERRED STOCK, WARRANTS OR UNITS UPON CONVERSION, EXCHANGE OR EXERCISE OF ANY OF SECURITIES.CHEMBIO DIAGNOSTICS INC - AGGREGATE INITIAL OFFERING PRICE OF THE SECURITIES THAT WE OFFER WILL NOT EXCEED $50 MILLION.
Full Article
March 8 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.16.Q4 REVENUE ROSE 40.7 PERCENT TO $6.0 MILLION.
Full Article
Feb 9 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES PRICING OF ITS PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 1.78 MILLION COMMON SHARES PRICED AT $6.75PER SHARE.
Full Article
Feb 8 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CHEMBIO DIAGNOSTICS INC - COMMENCED AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF ITS COMMON STOCK.
Full Article
Feb 8 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES MAJOR NEW TENDER WIN AND CERTAIN PRELIMINARY 2017 FINANCIAL RESULTS.SEES FY 2017 REVENUE $23.7 MILLION TO $24 MILLION.CHEMBIO - WON 3-YEAR TENDER FROM ETHIOPIA PHARMACEUTICALS FUND AND SUPPLY AGENCY TO DELIVER HIV 1/2 STAT-PAK ASSAY WITH CONTRACT VALUE $15.8 MILLION.COMPANY EXPECTS SHIPMENTS TO BEGIN DURING Q2 OF 2018 FOR ETHIOPIA PHARMACEUTICALS FUND AND SUPPLY AGENCY CONTRACT.CASH AND CASH EQUIVALENTS ARE ESTIMATED TO BE APPROXIMATELY $3.7 MILLION AS OF DECEMBER 31, 2017.
Full Article
Dec 20 (Reuters) - Chembio Diagnostics Inc ::CHEMBIO DIAGNOSTICS ANNOUNCES APPOINTMENT OF NEIL A. GOLDMAN AS CHIEF FINANCIAL OFFICER.CHEMBIO DIAGNOSTICS - GOLDMAN SUCCEEDS RICHARD J. LARKIN, WHO HAS SERVED AS CO'S EXECUTIVE VICE PRESIDENT AND CHIEF FINANCIAL OFFICER SINCE 2003.
Full Article
Dec 19 (Reuters) - Astrazeneca Plc ::CHEMBIO DIAGNOSTICS AND ASTRAZENECA ENTER A COLLABORATION TO DEVELOP POINT-OF-CARE DIAGNOSTIC TEST.CHEMBIO DIAGNOSTICS INC - UNDER TERMS OF 18-MONTH AGREEMENT, CO WILL RECEIVE UP TO $2.9 MILLION IN FUNDING FROM ASTRAZENECA.
Full Article
Earnings vs. 
Estimates